Pancreatic Cancer Research

ResearcherUniversity of JordanActive in the last 2 years

Zaed Z. R. Hamady

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-4591-5226; OpenAlex author ID A5005343839, A5122376093. Sources: OpenAlex.

Their work

Papers
19 (first author 1, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
59
Papers, trials and grants by year

2019: 2 papers · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 3 papers · 2024: 2 papers · 2025: 6 papers · 2026: 3 papers

Papers 19

  1. Risk-stratified surveillance for individuals in the UK at high risk of developing pancreatic cancer: Outcomes from the European Registry of Hereditary Pancreat… Co-author DOI 10.1016/j.ejca.2026.116592↗
  2. Clinicopathological differences and risk factors of early- versus late-onset pancreatic cancer: A systematic review and meta-analysis. Last author DOI 10.1016/j.isci.2026.116643↗
  3. Citrulline and Faecal Elastase 1 as a Combined Diagnostic Biomarker for Pancreatic Ductal Adenocarcinoma Co-author DOI 10.2139/ssrn.7472539↗
  4. Patterns, timing and predictors of recurrence following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: an international multicentre retrospectiv… Co-author DOI 10.1016/j.hpb.2024.11.015↗
  5. Development and validation of a diagnostic prediction model for pancreatic ductal adenocarcinoma: VAPOR 1, protocol for a prospective multicentre case-control … Co-author DOI 10.1136/bmjopen-2024-094505↗
  6. Utility of Polygenic Risk Scores (PRSs) in Predicting Pancreatic Cancer: A Systematic Review and Meta-Analysis of Common-Variant and Mixed Scores with Insights… First author DOI 10.3390/cancers17020241↗
  7. Metabolite Changes Associated with Resectable Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers17071150↗
  8. Venous Resection During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma-A Multicentre Propensity Score Matching Analysis of the Recurrence After Whi… Co-author DOI 10.3390/cancers17071223↗
  9. Physical Activity and Incident Pancreatic Cancer: Results From the UK Biobank Prospective Cohort. Last author DOI 10.7759/cureus.78040↗
  10. Five-year recurrence/survival after pancreatoduodenectomy for pancreatic adenocarcinoma: does pre-existing diabetes matter? Results from the Recurrence After W… Co-author DOI 10.1016/j.hpb.2024.04.010↗
  11. The role of aspirin in the prevention of pancreatic cancer: A nested case-control study in the UK Biobank. Last author DOI 10.1016/j.pan.2024.08.005↗
  12. Does an extensive diagnostic workup for upfront resectable pancreatic cancer result in a delay which affects survival? Results from an international multicentr… Co-author DOI 10.14701/ahbps.23-042↗
  13. Elevated Glycated Haemoglobin (HbA1c) Is Associated with an Increased Risk of Pancreatic Ductal Adenocarcinoma: A UK Biobank Cohort Study. Last author DOI 10.3390/cancers15164078↗
  14. Utilising Pancreatic Exocrine Insufficiency in the Detection of Resectable Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers15245756↗
  15. Predicting Pancreatic Cancer in the UK Biobank Cohort Using Polygenic Risk Scores and Diabetes Mellitus. Last author DOI 10.1053/j.gastro.2022.01.016↗
  16. DEPEND study protocol: early detection of patients with pancreatic cancer - a pilot study to evaluate the utility of faecal elastase-1 and 13C-mixed triglyceri… Last author DOI 10.1136/bmjopen-2021-057271↗
  17. Intraoperative radiotherapy for pancreatic cancer: implementation and initial experience. Co-author DOI 10.1093/bjs/znab335↗
  18. Identification of Cystic Lesions by Secondary Screening of Familial Pancreatic Cancer (FPC) Kindreds Is Not Associated with the Stratified Risk of Cancer. Co-author DOI 10.1038/s41395-018-0395-y↗
  19. Systemic neoadjuvant chemotherapy in modern pancreatic cancer treatment: a systematic review and meta-analysis. Last author DOI 10.1308/rcsann.2019.0060↗

Closest collaborators

The 25 strongest of 59 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Declan McDonnell · 7 shared papers, 2022–2026 · strength 1.83
  2. Paul R. Afolabi · 4 shared papers, 2022–2026 · strength 0.95
  3. Adam Enver Frampton · 4 shared papers, 2023–2025 · strength 0.66
  4. William Tapper · 2 shared papers, 2022–2025 · strength 0.59
  5. Andrew Malvern Smith · 4 shared papers, 2019–2026 · strength 0.58
  6. Umar H.K. Niazi · 2 shared papers, 2025–2026 · strength 0.57
  7. Stephen P. Pereira · 3 shared papers, 2019–2026 · strength 0.46
  8. Christopher Michael Halloran · 3 shared papers, 2019–2026 · strength 0.46
  9. Eithne Costello · 3 shared papers, 2019–2026 · strength 0.46
  10. Duncan R.C. Spalding · 3 shared papers, 2023–2025 · strength 0.45
  11. Keith John Roberts · 3 shared papers, 2023–2025 · strength 0.45
  12. Georgios‐Ioannis Verras · 1 shared paper, 2025 · strength 0.37
  13. Borna Ali Assarian · 1 shared paper, 2025 · strength 0.37
  14. Bilal A. Al-Sarireh · 2 shared papers, 2025 · strength 0.33
  15. George R. Buckland · 1 shared paper, 2024 · strength 0.31
  16. Paula Ghaneh · 2 shared papers, 2019–2026 · strength 0.29
  17. Guruprasad Padur Aithal · 2 shared papers, 2019–2026 · strength 0.29
  18. William Greenhalf · 2 shared papers, 2019–2026 · strength 0.29
  19. Alberto Porcu · 2 shared papers, 2023–2025 · strength 0.28
  20. Thomas Brendon Russell · 2 shared papers, 2023–2025 · strength 0.28
  21. Fabio Ausania · 2 shared papers, 2023–2025 · strength 0.28
  22. Ricky Harminder Bhogal · 2 shared papers, 2023–2025 · strength 0.28
  23. Somaiah Aroori · 2 shared papers, 2023–2025 · strength 0.28
  24. Ismael Domínguez-Rosado · 2 shared papers, 2023–2025 · strength 0.28
  25. Dhanny Gomez · 2 shared papers, 2023–2025 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.